For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with ...

Medera Inc. is a clinical-stage biopharmaceutical company, focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation gene- and cell-based approaches in ...

While the study is incomplete and preliminary, its strength lies in introducing hiPSC-CMs as a tool for investigating HFpEF mechanisms. A major weakness was found to be limited functional assessment ...

No randomized controlled trial has yet demonstrated a statistically significant reduction in mortality in HFmrEF or HFpEF, in contrast to HF with reduced EF (HFrEF), the researchers noted in a ...

FINEARTS-HF, she said, “also answers the question definitively” about whether MRAs reduce the risk of cardiovascular death or heart failure events in those with HFmrEF/HFpEF. “We know from other ...

In patients with heart failure (HF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), finerenone had a significantly lower rate of worsening HF events and cardiovascular-related death ...

HFPEF, which accounts for approximately half ... maximum oxygen consumption <85% of normal value, EF ≥40% with diastolic dysfunction evidence on echocardiogram, exercise for ≥3 minutes on ...

Kidney disease is common in heart failure with preserved ejection fraction (HFpEF). However, the biologic correlates and prognostic significance of kidney injury (KI), in HFpEF, beyond the estimated ...

For patients with heart failure with preserved ejection fraction, or HFpEF, the heart muscle contracts properly but the ventricles don’t relax, causing diminished blood flow. Obesity could be a ...

HFpEF patients were characterized by a high prevalence of left ... which documented benefit from sacubitril/valsartan among patients with HF with reduced EF. Lu H, Claggett BL, Packer M, et al.

Researchers combined data on nearly 4,000 patients across four trials who had heart failure with preserved ejection fraction (or HFpEF) and found that 5.4% of those treated with Wegovy experienced ...